PUBLISHER: QYResearch | PRODUCT CODE: 1872263
PUBLISHER: QYResearch | PRODUCT CODE: 1872263
The global market for Targeted RNA Sequencing was estimated to be worth US$ 2294 million in 2024 and is forecast to a readjusted size of US$ 7781 million by 2031 with a CAGR of 18.7% during the forecast period 2025-2031.
Targeted RNA Sequencing is a molecular biology technique that uses high-throughput sequencing to quantitatively analyze the expression of specific genes or gene regions. Unlike whole transcriptome sequencing, targeted RNA sequencing focuses on a defined gene panel, offering advantages such as lower cost, higher sensitivity, and simplified data processing. It is widely used in cancer subtyping, immune microenvironment profiling, drug target identification, genetic disease diagnostics, and single-cell expression analysis. With the proliferation of sequencing platforms and the advancement of multiplex PCR and probe hybridization technologies, targeted RNA sequencing has become a routine and powerful tool for clinical research institutions and biotech companies in the field of precision expression analysis.
As the concept of personalized treatment deepens and precision medicine advances, demand for targeted RNA sequencing continues to grow, especially in cancer and genetic disease applications. Government initiatives and sustained investments from pharma giants in biomarker development and bioinformatics are accelerating technology adoption in research labs and commercial institutions. Companies like Illumina and Thermo Fisher have reported a consistent CAGR of over 20% in targeted sequencing panel revenues, highlighting its growing role in genomic service portfolios. National funding surges in life sciences across the U.S., China, and Europe are further energizing the market.
Despite the promising outlook, the market faces challenges such as complex data interpretation, lack of standardization in workflows, and technical sensitivity to sample preparation. High-throughput sequencing platforms remain costly, creating adoption barriers for smaller labs and institutions. Additionally, increasingly stringent regulatory frameworks (e.g., IVD certifications, CLIA compliance) have extended timelines for clinical applications. Competitive pressure is also rising, with pricing becoming a pivotal factor and bargaining power concentrated among leading players.
Downstream demand is primarily driven by cancer research institutes, biopharma companies, and third-party CRO service providers. With the rise of cancer screening, liquid biopsy, and immunotherapy target development, the reliance on RNA-based companion diagnostics is intensifying. According to investment bank reports, targeted expression profiling is expanding its share within the RNA sequencing market and is expected to penetrate high-value segments such as solid tumor diagnostics, pediatric rare disease analysis, and quality control in cell therapy manufacturing over the next five years.
This report aims to provide a comprehensive presentation of the global market for Targeted RNA Sequencing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Targeted RNA Sequencing by region & country, by Type, and by Application.
The Targeted RNA Sequencing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted RNA Sequencing.
Market Segmentation
By Company
Segment by Type
Segment by Application
By Region
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Targeted RNA Sequencing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Targeted RNA Sequencing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Targeted RNA Sequencing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.